Literature DB >> 23182241

Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance.

Lorena López-Cerero1, María del Mar Bellido, Lara Serrano, Julia Liró, Jose Miguel Cisneros, Jesús Rodríguez-Baño, Alvaro Pascual.   

Abstract

INTRODUCTION: A multiresistant CTX-M-15-producing clonal group of Escherichia coli isolates, namely O25b:H4/ST131, has recently emerged in three continents. At this moment, appropriate studies to assess the real prevalence of this successful lineage are still scarce.
METHODS: In a prospective study in the south of Spain, among all clinical E. coli isolates recovered in Seville during a 30 week period in 2010, ST131 was screened by using PCR for O25b/pabB3/B23 traits. ESBL enzymes were characterized by PCR and sequencing. Genetic relatedness was performed by XbaI PFGE.
RESULTS: This clonal group was found to be prevalent (12.5% of all E. coli isolates), and only 37 (6.8% of ST131 isolates) were ESBL producers. Among 25 characterized ESBL-producing ST131 isolates, 96% harbored CTX-M-15. ST131 isolates were more frequently resistant to amoxicillin/clavulanate, aminoglycosides and fluoroquinolones in both ESBL and non-ESBL producers groups. XbaI PFGE performed on 88 ST131 isolates showed three pulsotypes, which included ≥4 isolates each (25% of all typed ST131 isolates), and 11 pulsotypes, which contained 2-3 isolates each. Three of 14 pulsotypes of this clonal group included both nalidixic acid-resistant and susceptible isolates, and five pulsotypes included both ESBL and non-ESBL producers.
CONCLUSIONS: Our findings suggest that O25b/ST131 is a prevalent clone in our area, and the observed prevalence of ESBL-producers within this clone is similar to that found in the total isolates of this species. Certain pulsotypes among ST131 clone that showed a greater expansion, and ESBL genes acquisition or quinolone resistance could explain part of this prevalence.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23182241     DOI: 10.1016/j.eimc.2012.09.005

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  7 in total

Review 1.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

2.  Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics.

Authors:  Jorge Blanco; Azucena Mora; Rosalia Mamani; Cecilia López; Miguel Blanco; Ghizlane Dahbi; Alexandra Herrera; Juan Marzoa; Val Fernández; Fernando de la Cruz; Luis Martínez-Martínez; María Pilar Alonso; Marie-Hélène Nicolas-Chanoine; James R Johnson; Brian Johnston; Lorena López-Cerero; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Clin Microbiol       Date:  2013-08-07       Impact factor: 5.948

3.  Long-Term Care Facilities Are Reservoirs for Antimicrobial-Resistant Sequence Type 131 Escherichia coli.

Authors:  Mary J Burgess; James R Johnson; Stephen B Porter; Brian Johnston; Connie Clabots; Brian D Lahr; James R Uhl; Ritu Banerjee
Journal:  Open Forum Infect Dis       Date:  2015-02-17       Impact factor: 3.835

Review 4.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

5.  Intestinal colonization due to Escherichia coli ST131: risk factors and prevalence.

Authors:  Isabel Morales Barroso; Lorena López-Cerero; María Dolores Navarro; Belén Gutiérrez-Gutiérrez; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Resist Infect Control       Date:  2018-11-15       Impact factor: 4.887

6.  Modelling the epidemiology of Escherichia coli ST131 and the impact of interventions on the community and healthcare centres.

Authors:  A Talaminos; L López-Cerero; J Calvillo; A Pascual; L M Roa; J Rodríguez-Baño
Journal:  Epidemiol Infect       Date:  2016-02-03       Impact factor: 4.434

Review 7.  Escherichia coli in Europe: an overview.

Authors:  Nerino Allocati; Michele Masulli; Mikhail F Alexeyev; Carmine Di Ilio
Journal:  Int J Environ Res Public Health       Date:  2013-11-25       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.